Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > BioNanomatrix Awarded Phase II NIH Grant to Support Development of Its Single-Molecule Nanoscale Whole Genome Analyzer

Abstract:
New $2.1 Million SBIR Grant Extends NHGRI Support for Commercial Development of the Company's Revolutionary Whole Genome Imaging and Analysis Platform

BioNanomatrix Awarded Phase II NIH Grant to Support Development of Its Single-Molecule Nanoscale Whole Genome Analyzer

Philadelphia, PA | Posted on March 17th, 2009

BioNanomatrix, Inc., a developer of breakthrough nanoscale platforms for biomedical research, molecular diagnostics and personalized medicine, today announced receipt of a Phase II grant from the National Human Genome Research Institute (NHGRI) of the U.S. National Institutes of Health (NIH). The grant is intended to support further commercial development of BioNanomatrix's nanoscale whole genome imaging and analysis platform. It follows the company's successful completion of work under a similar Phase I grant for initial development of the technology.

The 30-month $2.08 million Small Business Investment Research (SBIR) award was made under the BioEngineering Nanotechnology Initiative, an interdisciplinary, multi-institutes consortium with the stated goal of supporting the development of nanotechnologies critical for enabling essential breakthroughs that may have tremendous potential for affecting biomedicine.

"We are pleased that the NIH has again recognized the potential of our unique approach by awarding us this Phase II grant for the commercial development of our integrated nanoscale whole genome imaging and analysis platform," said Michael Boyce-Jacino, Ph.D., president and CEO of BioNanomatrix. "This additional funding will help support the commercial development of our potentially transformative technology."

Dr. Boyce-Jacino added, "BioNanomatrix's nanoscale technology is intended to allow researchers to directly image and analyze very long, individual intact strands of DNA at the single-molecule level with very high resolution, yielding a great deal of genomic information that is not currently accessible. We believe our technology has the potential to increase the utility of whole genome imaging and analysis for a wide range of research and diagnostic applications, and we are delighted at NHGRI's renewed vote of confidence in the potential of our program."

####

About BioNanomatrix
BioNanomatrix is developing breakthrough nanoscale whole genome imaging and analytic platforms for applications in biomedical research, genetic diagnostics and personalized medicine. The company is applying its expertise in nanochips, nanodevices and nanosystems to develop its patented platform technology to provide fast, comprehensive, and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Its current development efforts include a NIST-ATP funded project to sequence the human genome at a cost of $100. The company also receives funding from the National Institutes of Health. BioNanomatrix's technologies are licensed exclusively from Princeton University. Founded in 2003, the company is headquartered in Philadelphia, Pennsylvania. For more information, visit: www.BioNanomatrix.com

Contacts:
Barbara Lindheim
GendeLLindheim BioCom Partners
212-918-4650

Copyright © BioNanomatrix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

First Observation of Electronic Structure in Ag-Rh Alloy Nanoparticles Having Hydrogen Absorbing: Storage Property –Attempting to solve the mystery of why Ag-Rh alloy nanoparticles have a similar property to Pd– October 30th, 2014

Iranians Present Model to Predict Photocatalytic Process in Removal of Pollutants October 30th, 2014

Production of Biocompatible Polymers in Iran October 30th, 2014

Amorphous Coordination Polymer Particles as alternative to classical nanoplatforms for nanomedicine October 30th, 2014

Investments/IPO's/Splits

TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014

Arrowhead Issues Open Letter to Shareholders October 9th, 2014

PEN Inc. Announces New Trading Symbol: PENC: Stock Continues Trading on the OTCQB September 3rd, 2014

Aspen Aerogels, Inc. to Present at Barclays CEO Energy-Power Conference August 27th, 2014

Nanomedicine

Production of Biocompatible Polymers in Iran October 30th, 2014

Amorphous Coordination Polymer Particles as alternative to classical nanoplatforms for nanomedicine October 30th, 2014

'Electronic skin' could improve early breast cancer detection October 29th, 2014

Tiny carbon nanotube pores make big impact October 29th, 2014

Announcements

First Observation of Electronic Structure in Ag-Rh Alloy Nanoparticles Having Hydrogen Absorbing: Storage Property –Attempting to solve the mystery of why Ag-Rh alloy nanoparticles have a similar property to Pd– October 30th, 2014

Iranians Present Model to Predict Photocatalytic Process in Removal of Pollutants October 30th, 2014

Production of Biocompatible Polymers in Iran October 30th, 2014

Amorphous Coordination Polymer Particles as alternative to classical nanoplatforms for nanomedicine October 30th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE